AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from the ...
Goldman Sachs CEO David Solomon's 2025 compensation rises over 20% Goldman Sachs said on Friday CEO David Solomon's total annual compensation rose 20.5% to $47 million for 2025 after a strong year for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results